Views & Analysis Artificial Intelligence for better antibody drugs: ready for... The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion.
Events Partner Content 5th Annual Targeted Protein Degradation Summit Deliver Next Generation Degraders to Patients Faster
Events Partner Content 9th Annual Neurodegenerative Drug Development Summit Translate Neurodegenerative R&D Into the Clinic
News Lilly adds another sales channel for obesity drug Zepbound Telehealth firm Ro will offer low-cost, single-dose vials of Lilly's obesity drug Zepbound, the first alternative to the new LillyDirect DTC channel.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.